NSCLC Coverage From Every Angle

Published Medical Literature

Surgery Type for Lung Cancer May Influence Later Opioid Use
Epigenetic Alterations and Tumor Mutational Burden in NSCLC
Does Early CT Screening for Lung Cancer Reduce Mortality?
Do Brain Metastases Affect Outcomes With Immunotherapy?
Can Salvage Treatment Improve Survival in Early-Stage Lung Cancer?
Impact of Neoadjuvant Erlotinib on Radical Resection Rate in Patients With NSCLC
Acquired Osimertinib Resistance in EGFR-Positive NSCLC
Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?
New Test May Help Risk Stratify Patients With NSCLC for Treatment
Osimertinib Treatment in T790M-Positive NSCLC With CNS Metastases
Should Cisplatin Accompany First-Line NSCLC Treatment in Elderly Patients?
Review Features Clinical Challenges of Personalized Treatment in NSCLC
ERBB Mutation as Predictive Biomarker for Afatinib Treatment in Lung Cancer
Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?
Addition of Biomarker Panel to Lung Cancer Screening: Can It Improve Detection of Disease?
Retrospective Analysis of Brain Metastases in Patients With Stage IV NSCLC
Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?
Brigatinib Active in Patients With ALK-Positive Lung Cancer
Overall Survival Benefit of Crizotinib in Patients With ALK-Positive NSCLC
How Accurate Are Lung Cancer Risk Models for Selecting Ever-Smokers for Screening?
Screening for Intracranial Disease in Patients With Lung Cancer Versus Breast Cancer
ASTRO Updates Guideline for Palliative Radiation Therapy for Lung Cancer
Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer
Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?
Risk of Brain Metastases in Patients With NSCLC
Updated ASTRO Guideline Focuses on Palliative Radiotherapy for Lung Cancer
Review Offers 2018 Roadmap for Treating Advanced Non–Small Cell Lung Cancer
Geographic Disparity Observed in Lung Cancer Deaths in Women
Hypoxia as Therapeutic Target in Non–Small Cell Lung Cancer
Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer
Update on Genomic Testing for Patients With Lung Cancer
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer
Risk of Second Primary Lung Cancer After Treatment of Primary Lung Tumor
ASCO Endorses Molecular Testing Guideline Update for TKI Treatment in Lung Cancer
Update on Treatment of Oligometastatic Lung Cancer
Targeted Next-Generation Sequencing for Predicting Treatment Response in Lung Cancer
Targeted Radiation vs. Surgery for Early-Stage Lung Cancer
Osimertinib in Treating CNS Metastases From Lung Cancer
Combination Therapy for Previously Untreated Advanced Lung Cancer
Chemoradiation Versus Radiation Alone in Elderly Patients With Lung Cancer
Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer
Radiosurgery vs. Whole-Brain Radiation for Brain Metastases in Patients With Lung Cancer
Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?
Osimertinib as First-line Treatment of EGFR-Mutant Advanced NSCLC
Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer
Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer
Dacomitinib vs. Gefitinib in First-Line Treatment of EGFR Mutation–Positive NSCLC
Gefitinib Plus Chemotherapy in the IMPRESS Trial: Final Overall Survival
Does Adding Motesanib to Paclitaxel/Carboplatin Improve Outcomes in East Asian Patients With Lung Cancer?
Icotinib vs. Chemotherapy in EGFR-Positive Lung Adenocarcinoma
Dabrafenib and Trametinib in BRAF V600E–Mutant Metastatic NSCLC
Hair Repigmentation and Response to Immunotherapy for NSCLC
Consolidative Radiotherapy Prior to Chemotherapy for Limited Metastatic NSCLC
Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?
First-Line Treatment With Osimertinib in EGFR Mutation–Positive Advanced NSCLC
Pathologic Nodal Staging Quality and Survival Differences in Non–Small Cell Lung Cancer
Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer
Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC
Fat Intake and Risk of Lung Cancer
COPD Treatment Initiative for Patients With Lung Cancer
Frequency of Lung Cancer in Never-Smokers in the UK
Surfactant Protein D and Clinical Outcomes in Lung Cancer
Use of Supplemental Vitamin B and Risk of Lung Cancer
Comparing Chemotherapy Regimens With Gemcitabine and Cisplatin in Advanced NSCLC
Combination Therapy With Apatinib in Resistant NSCLC
Updated Molecular Analyses in NSCLC Patients Treated With Erlotinib
Driver Mutations and Therapy Selection for Lung Adenocarcinoma
Concurrent Chemotherapy and Proton Therapy in Advanced Lung Cancer
Robot-Assisted Thoracic Surgery for Lung Lobectomy in NSCLC
Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer
Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer
Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer
Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab
Alectinib and CNS Response in Resistant ALK-Positive Disease
Alectinib vs Crizotinib in ALK-Positive NSCLC
Potential Biomarker in Lung Squamous Cell Carcinoma
Early-Phase Trial of Vaccine in NSCLC
Brigatinib in Patients With Crizotinib-Refractory ALK–Positive NSCLC
Local Ablative Therapy for Oligometastatic Lung Cancer
Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer
Chromosome Instability: Potential Prognostic Predictor in Lung Cancer
Multikinase Inhibitors in RET-Rearranged NSCLC
A Population-Based Comparative Effectiveness Study of Chemoradiation Regimens and Sequences in Stage III NSCLC
Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer
Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous NSCLC
Proportion of Never-Smoker NSCLC Patients at Three Diverse Institutions
Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial
Management Strategies for Adverse Events Associated With EGFR TKIs in NSCLC
Treatment of Stage IIIA NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.